Clinical epidemiology applied to rheumatic and musculoskeletal diseases

The prevalence and burden of rheumatic and musculoskeletal diseases (RMDs) are predicted to increase because of the increasingly ageing population, placing greater demands on healthcare budgets. From the patient point of view, RMDs are the first cause of perceived disability. The objectivesof ECAMO team are to identifyrisk factors of poor prognosis, assess specific and effective treatments (both pharmacological and non-pharmacological)and thus decrease disability in patients with RMDs. The ultimate purpose is to providedata to adapt public health policies in the field.

  • New risk factors and co-morbidities

  • Evalutation criteria : Structural outcomes and Patients reported outcomes

  • Therapeutic strategies


  • Pr. Christian Roux
    Director of the team

  • Contact
    Denis Basse, administrative assistant

Major projects


National multicentric longitudinal observational cohort


National multicentric longitudinal observational cohort

See more

HODOREV project

Improve the attractiveness of physical exercises

 With high morbidity and disability rates, low back pain causes daily difficulties for patients (Vos et al., 2012). It is the number one cause of disability years in the world and the sixth in terms of reducing healthy life expectancy (Hoy et al., 2014). It is also the leading cause of disability at work (Palazzo et al., 2014), with an increasing incidence over the past 30 years.

See more

Other links

Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis

See more

Using Bayesian statistics to estimate the likelihood a new trial will demonstrate the efficacy of a new treatment

See more
Go to Top